Karolinska Development's portfolio company Forendo Pharma commences Phase 1b study of its drug candidate FOR-6219


STOCKHOLM – August 20, 2019. Karolinska Development (Nasdaq Stockholm: KDEV) announces today that its portfolio company Forendo Pharma has initiated dosing in a Phase 1b clinical study with the aim to demonstrate Proof of Mechanism for FOR-6219 – a drug candidate intended for the treatment of endometriosis.  

Endometriosis is a chronic condition that affects up to 10 per cent of women in reproductive age and causes repeated pain symptoms, infertility and impaired quality of life. Currently available treatments have limitations in efficacy or cause harmful side effects due to estrogen depletion. FOR-6219 is a HSD17B1 inhibitor aiming to reduce estrogen production locally in the endometriosis lesions.

In the Phase 1b study, FOR-6219 will be administered to healthy premenopausal women to explore its effect on the endometrium by measuring changes in endometrial thickness and endometrial estrogen levels. In addition to these local effects, systemic hormone levels will be measured. The study will also provide further safety and tolerability data.

“A positive outcome of this important Phase 1b study would further strengthen the hypothesis that Forendo Pharma’s lead drug candidate has potential to transform the treatment of endometriosis, based on its unique ability to selectively inhibit local estrogen production”, said Viktor Drvota, CEO of Karolinska Development.  

For further information, please contact :

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail:


About Karolinska Development AB
Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit



One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Följ GlobeNewswire

Abonnera på våra pressmeddelanden. Endast mejladress behövs och den används bara här. Du kan avanmäla dig när som helst.

Senaste pressmeddelandena från GlobeNewswire

Orange Industry 4.0 Campus welcomes co-innovation of Port of Antwerp, Borealis, Covestro and other industrial partners, maximizing 5G potential in the port of Antwerp22.1.2020 13:54:00 CETPress release

Press Release Brussels, 22 January 2020 Orange Industry 4.0 Campus welcomes co-innovation of Port of Antwerp, Borealis, Covestro and other industrial partners, maximizing 5G potential in the port of Antwerp Orange Belgium is now welcoming its first wave of industrial partners to the Orange Industry 4.0 Campus for business. The Port of Antwerp, the chemical company Borealis and high-tech polymer manufacturer Covestro started to co-innovate to developing real-life applications, maximizing the full potential of 5G at Orange Belgium’s testing hub. Deloitte Belgium will advise the community on shaping and realizing the business potential of this 5G innovation hub. With Orange’s 5G testing network being deployed on the campus, industrial partners will benefit from dedicated connectivity and a guaranteed service quality appropriate for their specific use cases. Orange Belgium launched this 5G testing network in Antwerp in late 2019 and it is the country’s first 5G stand-alone architecture net

Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation22.1.2020 11:45:00 CETPress release

ORION CORPORATION STOCK EXCHANGE RELEASE 22 JANUARY 2020 at 12.45 EET Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2020 AGM of Orion Corporation The Nomination Committee of Orion Corporation has on 22 January 2020 given to the company’s Board of Directors its recommendation for the proposal to the Annual General Meeting of 2020 concerning the composition of the Board of Directors to be elected by the meeting. The Committee recommends that the following proposal be presented to the AGM of 2020: The number of Board members would be seven. Of the present members of the Board, Pia Kalsta, Ari Lehtoranta, Timo Maasilta, Hilpi Rautelin, Eija Ronkainen and Mikael Silvennoinen would be re-elected for the next term of office and Kari Jussi Aho MSc (Econ. and Bus. Adm.) would be elected as a new member. Mikael Silvennoinen would be elected as Chairman of the Board. Silvennoinen has been a member of the Orion Board of Directors since 2014 and c

Orion publishes Financial Statement Release for 2019 on 5 February 202022.1.2020 08:00:00 CETPress release

ORION CORPORATION PRESS RELEASE 22 JANUARY 2019 at 09.00 EET Orion will publish its Financial Statement Release for 2019 on Wednesday, 5 February 2020 approximately at 12.00 noon EET. The release and related presentation material will be available on the company’s website at after publishing. News conference A news conference and a conference call for analysts, investors and media will be held on Wednesday, 5 January 2020 at 13.30 EET at Orion's head office, address Orionintie 1A, Espoo. Participants are requested to present a photo ID at the head office reception. A link to the live webcast will be available on Orion's website at A recording of the event will be available on the website later the same day. To participate the conference call, please dial: Finland: +358 9 817 103 10 Sweden: +46 8 566 426 51 UK: +44 33 3300 0804 USA: +1 855 857 0686 PIN: 45651029# Silent period The silent period preceding the publication is ongoing and

Prosafe SE: Q4 2019 results and webcast on 6 February 202022.1.2020 07:30:00 CETPress release

Prosafe SE will release its fourth quarter 2019 results on 6 February 2020 at approx. 07:00 a.m. CET. Jesper Kragh Andresen, CEO and Stig H. Christiansen, Deputy CEO & CFO will the same day at 10:00 a.m. CET present the results at Felix Konferansesenter, Bryggetorget 3, Oslo. The presentation can be followed live via web streaming at It will be possible to ask questions during the presentation by using the Q&A tool embedded in the webcast. The webcast will be available for replay at Prosafe is a leading owner and operator of semi-submersible accommodation vessels. The company is listed on the Oslo Stock Exchange with ticker code PRS. For more information, please refer to Stavanger, 22 January 2020 Prosafe SE For further information, please contact: Jesper K. Andresen, CEO Phone: +47 51 65 24 30 / +47 907 65 155 Stig Harry Christiansen, Deputy CEO and CFO Phone: +47 51 64 25 17 / +47 478 07 813 This information is subject to the disclosur

Basilea announces clinical supply agreement for its planned study FIDES-03 with derazantinib in gastric cancer22.1.2020 07:15:00 CETPress release

Extension of existing agreement with Roche for supply of PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®) Basel, Switzerland, January 22, 2020 – Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it extended its clinical supply agreement (CSA) with Roche (SIX: RO, ROG) to explore a combination of Basilea’s panFGFR kinase inhibitor derazantinib and Roche’s atezolizumab (Tecentriq®)1 in patients with gastric (stomach) cancer. The initial CSA covered urothelial (bladder) cancer and was concluded in January 2019. Basilea expects to start a biomarker-driven multi-cohort phase 1/2 study (FIDES-03) in advanced gastric cancer patients with FGFR genetic aberrations in the third quarter of 2020. The study will assess the efficacy and safety of derazantinib as mono- and combination therapy in the second-line setting. Basilea will be the sponsor of the study and Roche will provide clinical supply of atezolizumab, a PD-L1 checkpoint inhibitor. Dr. Marc Engelhardt, Chief Medical Officer